Therapeutic Potential of Linearol in Combination with Radiotherapy for the Treatment of Glioblastoma In Vitro

Int J Mol Sci. 2023 Feb 13;24(4):3760. doi: 10.3390/ijms24043760.

Abstract

Glioblastoma is one of the most malignant and lethal forms of primary brain tumors in adults. Linearol, a kaurane diterpene isolated from different medicinal plants, including those of the genus Sideritis, has been found to possess significant anti-oxidant, anti-inflammatory and anti-microbial properties. In this study, we aimed to determine whether linearol could exhibit anti-glioma effects when given alone or in combination with radiotherapy in two human glioma cell lines, U87 and T98. Cell viability was examined with the Trypan Blue Exclusion assay, cell cycle distribution was tested with flow cytometry, and the synergistic effects of the combination treatment were analyzed with CompuSyn software. Linearol significantly suppressed cell proliferation and blocked cell cycle at the S phase. Furthermore, pretreatment of T98 cells with increasing linearol concentrations before exposure to 2 Gy irradiation decreased cell viability to a higher extent than linearol or radiation treatment alone, whereas in the U87 cells, an antagonistic relationship was observed between radiation and linearol. Moreover, linearol inhibited cell migration in both tested cell lines. Our results demonstrate for the first time that linearol is a promising anti-glioma agent and further studies are needed to fully understand the underlying mechanism of this effect.

Keywords: glioblastoma; linearol; radiation; treatment.

MeSH terms

  • Brain Neoplasms* / metabolism
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation / radiation effects
  • Diterpenes* / therapeutic use
  • Glioblastoma* / metabolism
  • Glioma* / pathology
  • Humans

Substances

  • linearol
  • Diterpenes

Grants and funding

This research received no external funding.